Every year, business owners across British Columbia, Alberta, and Saskatchewan sit down to review their group benefits renewals, only to be struck by a sudden, jarring reality. The prescription drug portion of their plan—traditionally viewed as a stable, predictable line item—is climbing faster than almost any other cost center.
When you dig into the numbers, you find the culprit hiding in plain sight: the drug cost elephant.
Driven by an explosion in high-cost specialty medications, biologics for chronic inflammatory conditions, and the widespread surge in demand for GLP-1 therapies (such as Ozempic and Wegovy), private drug plans are absorbing unprecedented financial pressure. For a mid-sized business, a handful of high-cost claimants can single-handedly trigger a devastating double-digit rate hike at renewal.
Yet, when traditional brokers deliver the bad news, their playbook is predictably blunt. They recommend an all-or-nothing approach: either swallow the massive rate increase or implement sweeping cuts that hurt your entire workforce.
It is time to look past the panic and understand how specialty drug costs actually operate, why legacy plans are failing to manage them, and how proactive plan design can protect your bottom line without sacrificing employee care.
The Anatomy of the Drug Cost Spike
To understand why your renewal is spiking, you have to look at how modern pharmaceuticals have evolved. A decade ago, the vast majority of group drug claims were made up of low-cost, generic maintenance medications for things like cholesterol or mild blood pressure regulation.
Today, the pharmaceutical pipeline has shifted dramatically toward specialty drugs. These are complex, high-efficacy medications used to treat chronic, rare, or complex conditions like rheumatoid arthritis, Crohn’s disease, and severe metabolic disorders. While these therapies are incredible medical achievements that allow employees to remain healthy and productive, they come with a staggering price tag—often ranging from $10,000 to over $50,000 per year for a single individual.
Compounding this is the massive surge in utilization surrounding GLP-1 therapies. Initially developed for Type 2 diabetes, these medications have seen exponential demand for chronic weight management and metabolic health. With a significant percentage of Canadian adults dealing with weight-related chronic health risks, employees naturally expect their workplace benefits to support them.
The problem isn’t that your employees need these medications; the problem is that traditional, open-formulary group benefits plans were never built to handle them.
The Flaw of the “Open Formulary”
Under a traditional “open formulary” plan, virtually any drug approved by Health Canada is automatically covered from day one. There is little to no filtering for cost-effectiveness, no requirement for clinical validation unless triggered by extreme thresholds, and zero strategy for guiding employees toward equivalent lower-cost alternatives, such as biosimilars.
When you run an open formulary, you are essentially giving blank-check access to an escalating pharmaceutical market. If a few high-cost specialty claims hit your group in a given year, your insurance carrier’s experience-rating formula reacts by driving your premiums up aggressively.
Worse yet, many legacy brokers do nothing to help you manage this until the renewal letter arrives. They treat prescription claims as an uncontrollable act of nature. But letting your plan run unchecked on an open formulary is a strategic oversight.
Taming the Elephant: Modern Drug Management Strategies
You do not have to choose between financial ruin and stripping your employees of vital healthcare coverage. Modern plan design offers sophisticated, compassionate ways to manage specialty and high-cost medications without punishing your workforce.
- Implement a Managed Formulary: Moving from an open formulary to a managed formulary is one of the most effective ways to stabilize your plan. A managed formulary focuses on clinical efficacy, safety, and cost-effectiveness. It ensures your plan covers the best possible treatments while prioritizing evidence-based guidelines and encouraging the use of clinically equivalent alternatives when available. Plans utilizing managed formularies consistently experience lower per-claim costs across chronic categories.
- Prior Authorization Protocols: High-cost specialty drugs and complex therapies should always be subject to prior authorization. This ensures that the medication is being prescribed for an approved, medically necessary indication and that other first-line therapies have been explored. It prevents accidental over-insurance and ensures that every dollar spent is clinically justified.
- Smart Biosimilar Adoption: For biologic medications used in treatments like rheumatoid arthritis or colitis, shifting from original brand-name biologics to clinically proven biosimilars has become an essential cost-containment strategy. Biosimilars offer the exact same therapeutic benefit at a fraction of the cost, freeing up significant room in your plan’s budget to absorb other essential care.
- Targeted Chronic Disease Support: Obesity, diabetes, and metabolic health are interconnected challenges. Rather than reacting blindly to every GLP-1 claim, progressive employers are pairing coverage criteria with comprehensive chronic-care management programs, nutritional counselling, and lifestyle support. This ensures that medication is part of a holistic health strategy rather than an open-ended expense.
The Partner Advantage
Navigating the world of specialty drugs and pharmacy benefit management requires more than a calculator—it requires proactive guidance. A true broker partner doesn’t just hand you a higher bill at renewal; they analyze your claims data months in advance to identify cost drivers, implement modern formulary controls, and ensure your plan remains sustainable.
Your benefits plan should support your team’s long-term health while protecting your company’s financial health. It’s time to stop letting the drug cost elephant run amok in your budget.